Roche AG

Roche AG
Roche AG  
Discipline: Medicine/Pharmacology
Pharmacology - Mar 19
Tecentriq in combination with chemotherapy (carboplatin and etoposide) is the first and only cancer immunotherapy approved for the initial treatment of extensive-stage small cell lung cancer (ES-SCLC) First new initial treatment option approved by FDA for people with ES-SCLC in more than 20 years Roche today announced that the U.S.
Pharmacology - Mar 15

MabThera is the first biologic treatment approved for moderate to severe cases of the rare autoimmune disease pemphigus vulgaris (PV), and the first major advancement in the treatment of the disease in more than 60 years PV is a rare and potentially life-threatening blistering condition which can

Pharmacology - Mar 11

This Tecentriq combination is the first cancer immunotherapy regimen approved for breast cancer Triple-negative breast cancer is an aggressive disease, with high unmet medical need Roche today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Tecentriq (

Pharmacology - Mar 8

Approval based on significant survival benefit of Tecentriq in combination with Avastin, paclitaxel and carboplatin (chemotherapy) in people with metastatic non-squamous non-small cell lung cancer (NSCLC) compared with Avastin plus chemotherapy New treatment option for EGFR mutant or ALK-positive

Pharmacology - Mar 7

Application is being reviewed under FDA's Real-Time Oncology Review pilot programme Combination was granted Breakthrough Therapy Designation, the fifth for Venclexta Roche today announced the submission of a supplemental New Drug Application to the US Food and Drug Administration (FDA) for Vencle

Pharmacology - Feb 25

Roche to acquire Spark Therapeutics for US$ 114.50 per share Spark Therapeutics is a leader in discovering, developing and delivering gene therapies with one commercial asset and four programmes currently in clinical trials Transaction expected to close in Q2, 2019 Roche and Spark Therapeutics, Inc.

Pharmacology - Mar 14

First medicine to significantly reduce treated bleeds compared to prior factor VIII prophylaxis, in a prospective intra-patient comparison Only prophylactic medicine that can be given subcutaneously and with multiple dosing options The efficacy and safety of Hemlibra has been demonstrated in one

Health - Mar 11

PD-L1 (SP142) was the enrollment assay used in the IMpassion130 trial, the first positive phase III immunotherapy regimen study in triple-negative breast cancer Each year about 300,000 women are diagnosed globally with triple-negative breast cancer, an aggressive disease with limited treatment op

Health - Mar 7

Roche commences tender offer for all shares of Spark Therapeutics, Inc. for US$ 114.50 per share in cash Roche today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Spark Therapeutics, Inc.

Pharmacology - Feb 28

Roche today announced that the US Food and Drug Administration (FDA) has approved Herceptin Hylecta? (trastuzumab and hyaluronidase-oysk) for subcutaneous (under the skin) injection for the treatment of certain people with HER2-positive early breast cancer (node-positive, or node-negative and ER/

Pharmacology - Feb 19

Diffuse large B-cell lymphoma is an aggressive type of blood cancer that typically becomes harder to treat each time it returns Polatuzumab vedotin has shown significant potential to improve outcomes in people living with this disease Roche today announced that the U.S. Food and Dru

website preview


Medicine and Life Sciences